Auriculin A

Modify Date: 2024-02-28 16:47:04

Auriculin A structure	Common Name	Auriculin A
	CAS Number	91421-87-3	Molecular Weight	2542.81000
	Density	1.56	Boiling Point	N/A
	Molecular Formula	C₁₀₄H₁₆₈N₃₈O₃₃S₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Auriculin A

Auriculin A is a synthetic atrial natriuretic factor (ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits[1][2].

Name	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-guanidino-pentanoyl]amino]-3-hydroxy-propanoyl]amino]-3-hydroxy-propanoyl]amino]-19-(3-amino-3-oxo-propyl)-49-benzyl-34-(carboxymethyl)-31,40-bis(3-guanidinopropyl)-16-(hydroxymethyl)-10-isobutyl-22-methyl-28,37-bis[(1S)-1-methylpropyl]-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxo-butanoyl]amino]-3-hydroxy-propanoyl]amino]-3-phenyl-propanoyl]amino]-5-guanidino-pentanoic acid
Synonym	More Synonyms

Name

(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-guanidino-pentanoyl]amino]-3-hydroxy-propanoyl]amino]-3-hydroxy-propanoyl]amino]-19-(3-amino-3-oxo-propyl)-49-benzyl-34-(carboxymethyl)-31,40-bis(3-guanidinopropyl)-16-(hydroxymethyl)-10-isobutyl-22-methyl-28,37-bis[(1S)-1-methylpropyl]-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxo-butanoyl]amino]-3-hydroxy-propanoyl]amino]-3-phenyl-propanoyl]amino]-5-guanidino-pentanoic acid

Synonym

More Synonyms

Description	Auriculin A is a synthetic atrial natriuretic factor (ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
In Vivo	Auriculin A (0.3 μg/min/kg; i.v.; for 30 min) antagonizes renal vasoconstriction in the dog[1]. Auriculin A (2 μg/kg prime, 0.2 μg/kg/min; i.v.; for 45 min) influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits[2]. Animal Model: Female mongrel dogs used in early clamp experiments (15-20 kg, anesthetized with 30 mg/kg pentobarbital sodium i.v.)[1] Dosage: 0.3 μg/min/kg Administration: Intravenous injection; last for 30 min Result: Increased glomerular filtration rate (GFR) 16±4% and Na excretion (UNa V) 261±63%, whereas it decreased urine osmolality (Uosm) 36±7% without changing free water clearance. Also increased diuresis (V) and kaliuresis (UKV). Animal Model: New Zealand white male rabbits (3-3.5 kg, anesthetized with 50 mg/kg Chloralose (HY-B1020) and 500 mg/kg Urethane (HY-B1207) i.v.)[2] Dosage: 0.5 μg/kg prime, 0.05 μg/kg/min; 2 μg/kg prime, 0.2 μg/kg/min; 4 μg/kg prime, 0.4 μg/kg/min; 8 μg/kg prime, 0.8 μg/kg/min Administration: Intravenous injection; last for 30-60 min Result: Significantly reduced mean blood pressure and increased mean perfusion pressure at 4 μg/kg prime, 0.4 μg/kg/min dose, while heart rate did not change.